HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
Status:
Active, not recruiting
Trial end date:
2023-02-05
Target enrollment:
Participant gender:
Summary
A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect
of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP
Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers